Does ELRANATAMAB-BCMM Cause Malignant neoplasm progression? 27 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 27 reports of Malignant neoplasm progression have been filed in association with ELRANATAMAB-BCMM. This represents 4.7% of all adverse event reports for ELRANATAMAB-BCMM.
27
Reports of Malignant neoplasm progression with ELRANATAMAB-BCMM
4.7%
of all ELRANATAMAB-BCMM reports
14
Deaths
8
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ELRANATAMAB-BCMM?
Of the 27 reports, 14 (51.9%) resulted in death, 8 (29.6%) required hospitalization, and 3 (11.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELRANATAMAB-BCMM. However, 27 reports have been filed with the FAERS database.
What Other Side Effects Does ELRANATAMAB-BCMM Cause?
Cytokine release syndrome (115)
Death (51)
Pyrexia (46)
Fatigue (31)
Neoplasm progression (31)
Cytomegalovirus infection reactivation (29)
Off label use (27)
Immune effector cell-associated neurotoxicity syndrome (26)
Infection (25)
Cytomegalovirus infection (20)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ELRANATAMAB-BCMM Alternatives Have Lower Malignant neoplasm progression Risk?
ELRANATAMAB-BCMM vs ELTROMBOPAG
ELRANATAMAB-BCMM vs ELTROMBOPAG OLAMINE
ELRANATAMAB-BCMM vs ELUXADOLINE
ELRANATAMAB-BCMM vs ELVITEGRAVIR
ELRANATAMAB-BCMM vs EMAPALUMAB